Cyclophosphamide-induced cardiotoxicity is an uncommon complication especially in patients who have never undergone mediastinal irradiation or cardiotoxic chemotherapy and do not have underlying cardiac diseases. Here, we describe the case of a 19-year-old female with chronic myeloid leukemia. She was previously treated with oral tyrosine kinase inhibitors and developed cardiomyopathy after receiving infusion of 60 mg/kg intravenous cyclophosphamide for two days with a conditioning regimen for allogenic hematopoietic stem cell transplantation. Severe thickening of the left ventricle and reduced ejection fraction without triggering agents were characteristic for cyclophosphamide-induced cardiomyopathy. Her NT-pro BNP and troponin T concentrations surged to ＞70,000 pg/mL (0=130 pg/mL) and 2,031 pg/mL (0-14 pg/mL), respectively, during the course of the therapy and multiple organ failure seemed imminent evidenced by unresponsive decline in blood pressure. However, with close monitoring and persistent conservative management which consisted of intravenous hydration, continuous hemodialysis, and mechanical ventilation, her condition recovered.
Introduction
Cardiac dysfunction related to chemotherapy has become an important cause of morbidity and mortality in patients [1] . Common cardiovascular complications include left ventricular dysfunction, myocardial ischemia, hypertension, thromboembolism, QT prolongation, and bradycardia [2] .
Since many of these adverse effects significantly impact pa-tient's outcome, they have been an enormous concern for both cardiologists and oncologists.
Cyclophosphamide is a nitrogen mustard alkylating agent with potent antineoplastic, immunosuppressive, and immunomodulatory properties. Despite its use in cancer therapy and pretransplant stem cell conditioning regimens, the toxicity profile using distinctive dosing regimens has not been clarified [3] [4] [5] . Herein, we report the case of cyclophosphamide-induced cardiotoxicity occurring without an loading. Chest X-ray showed mild cardiomegaly with CT ratio of 0.60 compared to the previous X-ray with a ratio of 0.43 ( Fig. 1 ). Electrocardiography showed sinus rhythm echocardiography showed that left ventricular hypertrophy had resolved with an LV mass of 73 g/m 2 and decreased pericardial effusion (diameter, 8-10 mm). She is still in remission and has mostly returned to normal general condition, and we are planning to discharge her shortly.
Discussion
Cyclophosphamide-induced cardiotoxicity is a fatal condition that may lead to acute heart failure, pericardial effusion with tamponade, cardiogenic shock, and possibly death [1] . Heart failure has been associated with cyclophosphamide therapy in 7-28% of patients. The risk of cardiotoxicity is apparently dose-related (＞150 mg/kg and 1.5 g/m 2 /day) and occurs within 10 days of the administration of the first dose of cyclophosphamide [6] [7] [8] [9] . The risk factors also include the prior or concomitant use of other cardiotoxic agents, such as anthracyclines, previous mediastinal radiation, and pre-existing heart diseases [10] .
Although this patient did not have known risk factors and the total dose of cyclophosphamide was modest at 120 mg/kg, the morphological findings in the echocardiography -thickened myocardium, increased pericardial effusion, and a rather decreased ejection fraction-were compatible with cyclophosphamide-induced toxic myocarditis.
Considering the lack of established risk factors and the rapid progression of cyclophosphamide-induced cardiotoxicity, early detection of cardiac insult is of high interest. The most commonly used noninvasive method of monitoring cardiac toxicity from chemotherapeutic agents is echocardiography. Diastolic dysfunction, including a change in the E/A ratio, the interventricular septal thickness in diastole, and increased left ventricular diastolic and systolic diameters, are considered as the earliest predictors of cyclophosphamide damage [11, 12] . The patient showed a marked increase in the interventricular septal thickness in diastole and a marginal decrease in the left ventricular diastolic and systolic diameters (Fig. 2 , Table 2 ). Circulatory cardiac markers may also be a valuable predictor of chemotherapy-induced cardiac toxicity. B-type natriuretic peptide is perhaps the most promising indicator since it is elevated within the first 24 hours of therapy, and monitoring highly sensitive plasma cardiac troponin I or T may also have some advantages in predicting chemotherapy-induced myocardial damage [12] . The patient suffered from a sudden decline in blood pressure, and simultaneously, laboratory findings showed a significant increase in NT-pro BNP and troponin-T. 
